Trappsol Cyclo News Today

Founders Fund VI Management LLC purchased a new stake in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 110,023 shares of the company’s stock, valued at approximately $175,000. Cyclo Therapeutics comprises […]

Founders Fund V Management LLC bought a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics accounts for 80.8% of Founders Fund V Management […]

HC Wainwright assumed coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH – Free Report) in a research report sent to investors on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $3.00 target price on the stock. HC Wainwright also issued estimates for Cyclo Therapeutics’ Q1 2024 earnings at ($0.20) EPS, Q2 2024 […]

HC Wainwright began coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH – Free Report) in a research note published on Wednesday, Marketbeat Ratings reports. The firm issued a buy rating and a $3.00 price target on the stock. HC Wainwright also issued estimates for Cyclo Therapeutics’ Q1 2024 earnings at ($0.20) EPS, Q2 2024 earnings at […]

Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) – Analysts at HC Wainwright issued their Q1 2024 EPS estimates for Cyclo Therapeutics in a research note issued to investors on Wednesday, May 1st. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of ($0.20) per share for the quarter. HC Wainwright has a […]

Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Free Report) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 45,600 shares, a decrease of 59.5% from the March 15th total of 112,600 shares. Approximately 0.4% of the shares of the company are […]

Opthea (NASDAQ:OPT – Get Free Report) and Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends. Volatility & Risk Opthea has a beta of […]

Opthea (NASDAQ:OPT – Get Free Report) and Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation. Analyst Ratings This is a summary of current […]

Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) and Revolution Medicines (NASDAQ:RVMD – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership. Profitability This table compares Cyclo Therapeutics and Revolution […]

13.03.2024 - Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Increased ownership in Day Three Labs to a majority interest of 79% NEWARK, N.J., March 13, 2024 ...